Gsa Capital Partners LLP Neurocrine Biosciences Inc Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

A detailed history of Gsa Capital Partners LLP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 8,682 shares of NBIX stock, worth $1.19 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

8,682

Previous 1,604 441.27%

Holding current value

$1.19 Million

Previous $221,000 352.49%

% of portfolio

0.08%

Previous 0.02%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$114.58 - $153.15 $810,997 - $1.08 Million	7,078 Added 441.27%	8,682 $1 Million
Q2 2024 Aug 15, 2024	BUY	$130.86 - $143.19 $209,899 - $229,676	1,604 New	1,604 $221,000
Q3 2023 Nov 15, 2023	SELL	$94.02 - $117.1 $45,317 - $56,442	-482 Reduced 19.71%	1,964 $220,000
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $218,990 - $256,512	2,446 New	2,446 $230,000
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $894,953 - $1.07 Million	8,386 Added 220.51%	12,189 $1.46 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $121,755 - $142,632	-1,323 Reduced 25.81%	3,803 $404,000
Q2 2022 Aug 09, 2022	BUY	$75.79 - $100.07 $388,499 - $512,958	5,126 New	5,126 $500,000
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $389,488 - $519,415	-4,890 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $421,420 - $484,256	4,890 New	4,890 $469,000
Q4 2020 Feb 03, 2021	SELL	$86.91 - $108.33 $615,409 - $767,084	-7,081 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$96.16 - $135.15 $520,706 - $731,837	5,415 Added 325.03%	7,081 $681,000
Q2 2020 Aug 11, 2020	BUY	$85.09 - $130.36 $141,759 - $217,179	1,666 New	1,666 $203,000
Q1 2020 May 12, 2020	SELL	$75.11 - $113.76 $1.09 Million - $1.66 Million	-14,569 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$86.8 - $118.57 $819,392 - $1.12 Million	9,440 Added 184.05%	14,569 $1.57 Million
Q3 2019 Nov 12, 2019	SELL	$83.82 - $101.5 $383,141 - $463,956	-4,571 Reduced 47.12%	5,129 $462,000
Q2 2019 Aug 06, 2019	BUY	$72.24 - $91.27 $202,272 - $255,556	2,800 Added 40.58%	9,700 $819,000
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $242,585 - $320,355	-3,500 Reduced 33.65%	6,900 $608,000
Q4 2018 Feb 12, 2019	BUY	$68.32 - $124.36 $379,995 - $691,690	5,562 Added 114.96%	10,400 $743,000
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $478,381 - $608,862	4,838 New	4,838 $595,000
Q2 2018 Aug 09, 2018	SELL	$75.3 - $105.99 $183,054 - $257,661	-2,431 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$75.88 - $92.43 $184,464 - $224,697	2,431 New	2,431 $202,000

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Neurocrine Biosciences Inc Transaction History